Diabetes 

There are 589 million people worldwide suffering from diabetes, and it causes 3.4 million deaths annually. The diabetes drug market was nearly US $80 billion in 2025 and is projected to exceed US $153.4 billion by 2033.

This chart illustrates the changing market share of existing diabetes drugs. You can observe that small-molecule drugs are growing yearly. PS-001, a novel small-molecule drug, aligns perfectly with the current trend in diabetes pharmacotherapy.

Patients in the early and middle stages of the disease primarily use small-molecule drugs, which account for 55% of the current diabetes drug market. DPP4 inhibitors and GLP-1 analogues represent a relatively newer therapeutic area, with their market share continuously expanding, and they currently constitute 30% of the total diabetes drug market. Patients in advanced stages mainly use insulin and insulin analogues, which account for the remaining 45% of the diabetes drug market.

Our target is to capture the 30% market segment currently held by DPP4 inhibitors and GLP-1 analogues.